Abstract: Objective:To discuss effectual chemotherapeutic regimens of recurrent carcinoma of the cervix. Methods:A retrospective analysis and study of the data of 54patients with recurrent cervical cancer, who were treated with combined therapy of paclitaxel plus carboplatin/cisplatin with other drugs in the Cancer Hospital of Peking Union Medical College and Chinese Academy of Medical Sciences during the period from1998to 2007, were conducted. Results: Recurrence after rad-ical surgery occurred in 11of the 54patients, and post-radiotherapeutic relapse occurred in the other 43patients (including those undergoing postoperative radiotherapy). In 24of the 54patients, relapse occurred at the irradiated sites and in the other 30patients (including those without radiotherapy after undergoing initial surgery), the recurrent cancer occurred out-side of irradiated sites. The mean age of the patients at diagnosis of the recurrence was 46.7 ± 1.442 (range, 27-70) years, with a median of45. The mean recurrence time after initial surgery was 13.80± 2.34(range, 3-96) months, and the median time of the relapse was 8 months. The serum SCCAg rose in 43of the 54recurrent patients, with a ratio of 79.6%. Of the 54patients, 24were treated with paclitaxel plus cisplatin (PT) or carboplatin (PC), and12also received the same regimens because of progression of the disease after undergoing other cisplatin-based combined chemotherapy. Thirty of the 54pa-tients were treated with combined chemotherapy of cisplatin plus other drugs. In addition, 6 patients received PT or PC regi -men because of ineffective cisplatin-based chemotherapeutics. The overall response rate was 58.33% (14/24), including CR+PR, in the 24patients receiving PT or PC regimen, whereas the response rate was 40% (4/10) in the patients with recurrence at the irradiated sites, which was lower than that of 66.7% (10/14) in the patients with relapse outside of the irradi -ated sites. The response rate of 30patients receiving other cisplatin-based chemotherapeutics was 13.33% (4/30), where -as the response rate was 6.67% (1/15) in 15patients with recurrent disease at the irradiated sites and 20% (3/15) in anoth-er 15with the relapse outside the irradiated sites. The effectual rate was higher in the patients with PT or PC regimens than in those with cisplatin-based regimens ( 58.33% vs.13.33%,χ2 value = 14.351 , P<0.001 ). There were no significant differ -ences in comparison of the response rates between the patients with the relapses inside and outside the irradiated sites (66.7% vs.40%,χ2 value = 1.67, P=0.20, i.e. > 0.05). The median survival time of the 54patients was 10months and the mean survival time was11.96± 1.246 months (range, 3 ~ 54months). The 1- and 2-year overall survival rates were 48.9% and 26.33%, respectively. It was shown by univariate analysis that recurrent sites (inside or outside the irradiated field), tumor grading, chemotherapeutic regimens (PT or PC vs. other cisplatin-based combined therapy), decline of SCCAg during or after the chemotherapy and effectiveness of the chemotherapy significantly affect the survival rates (P <0.05), while only PT or PC chemotherapy and efficacy of chemotherapy were revealed by the multivariate analysis as the independent prog-nostic factors.Conclusion : According to our retrospective study, the combination therapy of paclitaxel with cisplatin or carbo -platin is more effective than the combined regimens of other cisplatin-based drugs in recurrent carcinomas of the cervix. However, further randomized studies are needed.